載入...
Evaluation of Consistency of Treatment Response Across Regions—the LEADER Trial in Relation to the ICH E17 Guideline
The US Food and Drug Administration in 2008 required new type 2 diabetes (T2D) medications to be subject to cardiovascular outcomes safety requirements. Accordingly, the global LEADER trial investigated cardiovascular outcomes of T2D treatment with liraglutide, a glucagon-like peptide-1 receptor ago...
Na minha lista:
| 發表在: | Front Med (Lausanne) |
|---|---|
| Main Authors: | , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Frontiers Media S.A.
2021
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8201994/ https://ncbi.nlm.nih.gov/pubmed/34136501 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fmed.2021.662775 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|